You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Details for New Drug Application (NDA): 019219

✉ Email this page to a colleague

NDA 019219 describes BETAGAN, which is a drug marketed by Allergan and is included in two NDAs. Additional details are available on the BETAGAN profile page.

The generic ingredient in BETAGAN is levobunolol hydrochloride. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levobunolol hydrochloride profile page.

Summary for 019219

Tradename:	BETAGAN
Applicant:	Allergan
Ingredient:	levobunolol hydrochloride
Patents:	0

Medical Subject Heading (MeSH) Categories for 019219

Adrenergic beta-Antagonists
Sympatholytics

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION/DROPS;OPHTHALMIC			Strength	0.5%
Approval Date:	Dec 19, 1985	TE:	AT	RLD:	Yes

Expired US Patents for NDA 019219

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	BETAGAN	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019219-002	Dec 19, 1985	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.